Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.